Results 91 to 100 of about 4,120 (178)

Publication Only

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

A closed-loop cell therapy engineered to autonomously secrete activin A inhibitor protects from fibrodysplasia ossificans progressiva

open access: yesiScience
Summary: Engineered cell therapies present an opportunity for endogenous, site-specific production of therapeutic agents. Fibrodysplasia ossificans progressiva (FOP) is a morbid condition in which patients develop extensive heterotopic bony lesions in ...
Pratik Koirala   +9 more
doaj   +1 more source

ACVR1 Allele-Specific Antisense Oligonucleotides

open access: yes
IPFS: QmNPT5Mzt9mwnFUreNhNsjjm4fECQT9Xjf5MNyAgT5pDMi. TX: 0xc6ffa10bd0cd44e5c98d54fe485efc5d46a4aaf1936f8bec57c4ea97a478c0b9. CC0.
openaire   +1 more source

Imatinib Repurposing for ACVR1 Downstream Signaling Inhibition

open access: yes
IPFS: QmQp88cmTnfSNBeTvggvrqUSDn52KZcMXnUUUG6GwoJWNV. TX: 0x5d6e87921cd14d0ed369673eb4b9420a0b8f22cebd7cb561052d47a78accde68. CC0.
openaire   +1 more source

Fibrodysplasia ossificans progressiva in children: diagnostic pitfalls and ACVR1 genotype-phenotype spectrum. [PDF]

open access: yesEur J Pediatr
Acikgoz NB   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy